(24/7 MARKET NEWS) – Monopar Therapeutics Inc. (NASDAQ: MNPR) reported, this morning, an update from its currently enrolling multi-center open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS) and 3 of 3 patients in the 520 mg/m2 cohort achieved stable disease
Monopar Therapeutics is trading at $1.151, up $0.173 (+17.68%), on 1.22M premarket shares traded.
Its 52-week range is $0.8105 to $4.88. Its May 30 run will provide multiple resistance points, so it’ll need massive trading volume to make a meaningful move.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.